22nd Century Group Stock Price, News & Analysis (NYSEAMERICAN:XXII)

$2.65 0.04 (1.53 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$2.65
Today's Range$2.60 - $2.71
52-Week Range$0.81 - $3.50
Volume2.03 million shs
Average Volume2.50 million shs
Market Capitalization$327.44 million
P/E RatioN/A
Dividend YieldN/A
Beta2.97

About 22nd Century Group (NYSEAMERICAN:XXII)

22nd Century Group logo22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.

Receive XXII News and Ratings via Email

Sign-up to receive the latest news and ratings for XXII and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Environmental Biotechnology
Sub-IndustryCannabis
SectorIndustrials
SymbolNYSEAMERICAN:XXII
CUSIPN/A
Phone+1-716-2701523

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.13)
Net IncomeN/A
Net Margins-73.20%
Return on Equity-50.30%
Return on Assets-43.77%

Miscellaneous

EmployeesN/A
Outstanding Shares123,560,000

22nd Century Group (NYSEAMERICAN:XXII) Frequently Asked Questions

What is 22nd Century Group's stock symbol?

22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII."

How were 22nd Century Group's earnings last quarter?

22nd Century Group Inc (NYSEAMERICAN:XXII) released its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($0.03) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.01. The biotechnology company had revenue of $4.53 million for the quarter, compared to analysts' expectations of $5.09 million. 22nd Century Group had a negative net margin of 73.20% and a negative return on equity of 50.30%. The company's revenue for the quarter was up 46.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.03) EPS. View 22nd Century Group's Earnings History.

When will 22nd Century Group make its next earnings announcement?

22nd Century Group is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for 22nd Century Group.

Where is 22nd Century Group's stock going? Where will 22nd Century Group's stock price be in 2017?

1 equities research analysts have issued 1-year target prices for 22nd Century Group's stock. Their predictions range from $11.50 to $11.50. On average, they anticipate 22nd Century Group's share price to reach $11.50 in the next year. View Analyst Ratings for 22nd Century Group.

What are Wall Street analysts saying about 22nd Century Group stock?

Here are some recent quotes from research analysts about 22nd Century Group stock:

  • 1. According to Zacks Investment Research, "22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. " (10/18/2017)
  • 2. Chardan Capital analysts commented, "We expect 22nd Century to report Q4 results this week. Our revenue estimate for the quarter is $3.1 million, equivalent to Q3 results. For the full year this results in revenue of $12 million. We expect the company on its earnings call to focus on recent communications with the FDA regarding its PMTA (Premarket Tobacco Product Applications), the MRTP (Modified Risk Tobacco Product) applications and a path forward for X-22. Earlier this month the FDA granted a guidance meeting to discuss X-22 and the ways 22nd Century could attempt to win approval for X-22 as a prescription-based aid for smoking cessation. The company has also received written feedback on the MRTP application for Brand A, the company's very low nicotine (VLN) cigarette. As we progress through the year we expect additional milestones to be reached on 22nd Century's attempt to use its proprietary technology to create VLN products for the smoking cessation market." (3/7/2017)

Are investors shorting 22nd Century Group?

22nd Century Group saw a increase in short interest in November. As of November 30th, there was short interest totalling 9,244,966 shares, an increase of 8.9% from the November 15th total of 8,488,763 shares. Based on an average daily volume of 2,012,038 shares, the short-interest ratio is currently 4.6 days. Approximately 8.7% of the company's shares are short sold.

Who are some of 22nd Century Group's key competitors?

Who are 22nd Century Group's key executives?

22nd Century Group's management team includes the folowing people:

  • Henry Sicignano III, President, Chief Executive Officer, Director (Age 48)
  • John T. Brodfuehrer, Chief Financial Officer, Treasurer (Age 58)
  • Thomas L. James Esq., Vice President, General Counsel, Secretary (Age 57)
  • Paul Rushton Ph.D., Vice President - Plant Biotechnology (Age 53)
  • Michael R. Moynihan Ph.D., Vice President - Research & Development (Age 63)
  • James W. Cornell, Non-Executive Independent Chairman of the Board (Age 58)
  • Nora B. Sullivan, Director (Age 58)
  • Joseph Alexander Dunn Ph.D., Independent Director (Age 62)
  • Richard M. Sanders, Independent Director (Age 62)

Who owns 22nd Century Group stock?

22nd Century Group's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (0.10%), Advisor Group Inc. (0.07%), Bristol Advisors LLC (0.07%), Wells Fargo & Company MN (0.07%) and Steward Partners Investment Advisory LLC (0.03%). Company insiders that own 22nd Century Group stock include John T Brodfuehrer and Michael Robert Moynihan. View Institutional Ownership Trends for 22nd Century Group.

Who bought 22nd Century Group stock? Who is buying 22nd Century Group stock?

22nd Century Group's stock was bought by a variety of institutional investors in the last quarter, including Bristol Advisors LLC, Wells Fargo & Company MN, Steward Partners Investment Advisory LLC, Bank of New York Mellon Corp and Advisor Group Inc.. View Insider Buying and Selling for 22nd Century Group.

How do I buy 22nd Century Group stock?

Shares of 22nd Century Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is 22nd Century Group's stock price today?

One share of 22nd Century Group stock can currently be purchased for approximately $2.65.

How big of a company is 22nd Century Group?

22nd Century Group has a market capitalization of $327.44 million.

How can I contact 22nd Century Group?

22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523.


MarketBeat Community Rating for 22nd Century Group (XXII)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  204
MarketBeat's community ratings are surveys of what our community members think about 22nd Century Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

22nd Century Group (NYSEAMERICAN:XXII) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.50$11.50$3.50$3.50
Price Target Upside: 1,110.53% upside1,110.53% upside268.42% upside268.42% upside

22nd Century Group (NYSEAMERICAN:XXII) Consensus Price Target History

Price Target History for 22nd Century Group (NYSEAMERICAN:XXII)

22nd Century Group (NYSEAMERICAN:XXII) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
10/16/2017Chardan CapitalBoost Price TargetBuy$3.50 -> $11.50View Rating Details
(Data available from 12/16/2015 forward)

Earnings

22nd Century Group (NYSEAMERICAN:XXII) Earnings History and Estimates Chart

Earnings by Quarter for 22nd Century Group (NYSEAMERICAN:XXII)

22nd Century Group (NYSEAMERICAN XXII) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018($0.02)N/AView Earnings Details
11/9/2017Q3 2017($0.02)($0.03)$5.09 million$4.53 millionViewN/AView Earnings Details
5/10/2016Q1($0.03)($0.04)$3.02 millionViewN/AView Earnings Details
11/9/2015Q3($0.03)($0.04)$2.67 millionViewN/AView Earnings Details
8/4/2015Q215($0.02)($0.02)$1.30 million$2.31 millionViewN/AView Earnings Details
2/6/2015($0.03)($0.09)ViewN/AView Earnings Details
11/14/2014Q314($0.03)($0.05)$0.06 millionViewN/AView Earnings Details
8/14/2014($0.03)($0.03)$0.02 millionViewN/AView Earnings Details
5/2/2014($0.03)($0.09)$0.45 millionViewN/AView Earnings Details
1/30/2014Q4($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

22nd Century Group (NYSEAMERICAN:XXII) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for 22nd Century Group (NYSEAMERICAN:XXII)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

22nd Century Group (NYSEAMERICAN XXII) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for 22nd Century Group (NYSEAMERICAN:XXII)
Institutional Ownership by Quarter for 22nd Century Group (NYSEAMERICAN:XXII)

22nd Century Group (NYSEAMERICAN XXII) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/29/2017Michael Robert MoynihanVPSell50,000$2.67$133,500.00View SEC Filing  
7/31/2017Michael Robert MoynihanVPSell29,532$2.00$59,064.00View SEC Filing  
6/8/2017Michael Robert MoynihanVPSell20,468$2.00$40,936.00View SEC Filing  
10/31/2016Michael Robert MoynihanVPSell100,000$1.28$128,000.00View SEC Filing  
3/29/2016John T BrodfuehrerCFOBuy12,500$0.77$9,625.00View SEC Filing  
11/3/2015Michael Robert MoynihanVPSell50,000$1.40$70,000.00View SEC Filing  
6/30/2015Joseph PandolfinoDirectorSell91,178$0.95$86,619.10View SEC Filing  
12/31/2014Joseph PandolfinoDirectorSell105,124$1.65$173,454.60View SEC Filing  
12/26/2014Joseph PandolfinoDirectorSell41,722$1.54$64,251.88View SEC Filing  
12/22/2014Joseph PandolfinoDirectorSell52,683$1.60$84,292.80View SEC Filing  
12/17/2014Joseph PandolfinoDirectorSell75,768$1.62$122,744.16View SEC Filing  
12/11/2014Joseph PandolfinoDirectorSell67,836$1.65$111,929.40View SEC Filing  
5/9/2014Richard M SandersDirectorBuy20,000$2.23$44,600.00View SEC Filing  
4/23/2014Michael Robert MoynihanVPSell100,000$2.44$244,000.00View SEC Filing  
3/12/2014Joseph PandolfinoCEOSell95,000$5.73$544,350.00View SEC Filing  
12/10/2013Clearwater Partners, LlcMajor ShareholderSell10,000$1.55$15,500.00View SEC Filing  
12/3/2013Clearwater Partners, LlcMajor ShareholderSell10,000$1.35$13,500.00View SEC Filing  
11/19/2013Clearwater Partners, LlcMajor ShareholderSell30,074$1.09$32,780.66View SEC Filing  
11/13/2013Clearwater Partners, LlcMajor ShareholderSell11,826$0.98$11,589.48View SEC Filing  
11/11/2013Clearwater Partners, LlcMajor ShareholderSell7,100$1.03$7,313.00View SEC Filing  
11/7/2013Clearwater Partners, LlcMajor ShareholderSell9,000$1.15$10,350.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

22nd Century Group (NYSEAMERICAN XXII) News Headlines

Source:

SEC Filings

22nd Century Group (NYSEAMERICAN:XXII) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

22nd Century Group (NYSEAMERICAN XXII) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.